Stay updated on Pembrolizumab +/- Radiation in Adenoid Cystic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- Radiation in Adenoid Cystic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab +/- Radiation in Adenoid Cystic Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedFooter now shows Revision: v3.4.2, replacing the previous government-activity notices tied to older revisions. This is a minor maintenance update unrelated to study content or user actions.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and NIH operating status. Updated the site to Revision 3.4.1, replacing Revision 3.4.0.SummaryDifference0.5%

- Check28 days agoChange DetectedChanges are minor UI/label updates (glossary toggle, capitalization tweaks, and a Revision: v3.4.0 label) that do not alter study content or outcomes; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a dedicated Locations section with Massachusetts as a site and removed the old Massachusetts Locations header and the HHS Vulnerability Disclosure link due to content reorganization.SummaryDifference0.2%

- Check85 days agoChange DetectedMinor page revision updated from v3.3.1 to v3.3.2; no changes to study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab +/- Radiation in Adenoid Cystic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- Radiation in Adenoid Cystic Carcinoma Clinical Trial page.